X

Trial Profile

A Phase Ib Study of Pembrolizumab (MK-3475) in Chinese Subjects With Locally Advanced or Metastatic Melanoma (Keynote-151)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms Keynote-151; MK-3475-151/KEYNOTE-151
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

24 Oct 2023 Results of more than 5 y of follow-up were presented at the 48th European Society for Medical Oncology Congress.
06 Dec 2022 Status changed from active, no longer recruiting to completed.
29 Jul 2022 Planned End Date changed from 31 Jul 2022 to 30 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com